Therefore, development of ZNF304 or FOXO4 agonists or the use of technologies such as CRISPR-Cas9 (32, 33) to target upregulation of these genes expression, or the use of miR-183-5p antagonists are expected to achieve the inhibition of tumor progression. This evidence concerns the gene ZNF304 and neoplasm.